Blepharitis Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Akorn Inc., Allergan Plc, Bausch Health Companies, Inc., Novartis AG and Pfizer Inc., Nicox Ophthalmics

The Key Blepharitis Companies in the market include - Famy Life Sciences, Tarsus Pharmaceuticals, Akorn Inc., Allergan Plc, Bausch Health Companies, Inc., Novartis AG and Pfizer Inc., Nicox Ophthalmics, Inc., Laboratoires Thea, Sun Pharmaceutical, LianBio LLC, Merck Sharp & Dohme, AxeroVision, Inc., Alcon Research, Ursapharm Arzneimittel, Galderma R&D, Kala Pharmaceuticals, and others.

DelveInsight's "Blepharitis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Blepharitis, historical and forecasted epidemiology as well as the Blepharitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Blepharitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Blepharitis Market Forecast [https://www.delveinsight.com/sample-request/blepharitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Blepharitis Market Report:

*
The Blepharitis market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In August 2025, The "one-drug-many-indications" approach has gained momentum since the early 2000s. Tarsus Pharmaceuticals, based in Irvine, California, is applying this strategy to XDEMVY (lotilaner), an antiparasitic originally approved by the FDA for use in dogs. After acquiring rights from Elanco, Tarsus secured FDA approval of XDEMVY for treating Demodex blepharitis, an eye condition caused by mites. By July 2023, the drug generated $102.7 million in net sales in Q2 2025, marking a 152% year-over-year growth.

*
In July 2025, Viatris Inc. (Nasdaq: VTRS), a global healthcare company, reported that its randomized, double-masked, vehicle-controlled Phase 3 trial evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in patients with blepharitis failed to achieve its primary endpoint of complete debris resolution after six weeks of twice-daily treatment.

*
In the United States, ophthalmologists diagnose blepharitis in approximately 20% to 30% of their patients.

*
In Italy, anterior blepharitis accounted for approximately 12% of all blepharitis cases, while posterior blepharitis made up around 24%.

*
Demodex infestation was detected in 50% to 80% of patients with blepharitis.

*
The blepharitis pipeline includes promising drugs such as NCX 4251, Pimecrolimus 0.3%, and others.

*
According to the American Academy of Ophthalmology (2023), blepharitis was detected in 37% to 47% of patients in the United States who were seen by respondents

*
Demodex blepharitis can afflict people of all ages, according to a study by John Meyer (2022), and its prevalence rises with age, affecting more than 80% of people over the age of 60 and 100% of those over the age of 70

*
According to the Atlas study (2022), 51% of patients have had demodex blepharitis symptoms for more than 4 years, and 58% of patients have never had a blepharitis diagnosis

*
More than 50% of individuals under the age of 18 in a research by Stanley et al. (2022) reported having blepharitis symptoms for four or more years. About 47% of people stated they were constantly aware of their eyes, and 23% said they worried about their eyes constantly

*
Key Blepharitis Companies: Famy Life Sciences, Tarsus Pharmaceuticals, Akorn Inc., Allergan Plc, Bausch Health Companies, Inc., Novartis AG and Pfizer Inc., Nicox Ophthalmics, Inc., Laboratoires Thea, Sun Pharmaceutical, LianBio LLC, Merck Sharp & Dohme, AxeroVision, Inc., Alcon Research, Ursapharm Arzneimittel, Galderma R&D, Kala Pharmaceuticals, and others

*
Key Blepharitis Therapies: XDEMVY, Pimecrolimus 0.3% ophthalmic ointment, TP-03, PMP2207, Erythromycin, NCX 4251, Azithromycin, Fluticasone Propionate, ISV-502, Lotilaner, AzaSite Registered , AXR-270, Tobradex ST, Posiformin, COL-101, KPI-121, Moxifloxacin, and others

*
The Blepharitis epidemiology based on age-specific cases analyzed that Blepharitis is more common in individuals older than the age of 50

*
The Blepharitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Blepharitis pipeline products will significantly revolutionize the Blepharitis market dynamics.

Blepharitis Overview

Blepharitis is a common eye condition characterized by inflammation of the eyelids, particularly at the base of the eyelashes. It often causes redness, swelling, itching, and a burning sensation, sometimes accompanied by crusting or flaking. Blepharitis can result from bacterial infection, skin conditions like seborrheic dermatitis, or dysfunction of the oil glands (meibomian glands). While it is usually chronic and not vision-threatening, proper eyelid hygiene, warm compresses, and sometimes medicated treatments are needed to manage symptoms and prevent flare-ups.

Get a Free sample for the Blepharitis Market Report:

https://www.delveinsight.com/report-store/blepharitis-market [https://www.delveinsight.com/report-store/blepharitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Blepharitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Blepharitis Epidemiology Segmentation:

The Blepharitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Blepharitis

*
Prevalent Cases of Blepharitis by severity

*
Gender-specific Prevalence of Blepharitis

*
Diagnosed Cases of Episodic and Chronic Blepharitis

Download the report to understand which factors are driving Blepharitis epidemiology trends @ Blepharitis Epidemiology Forecast [https://www.delveinsight.com/sample-request/blepharitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Blepharitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Blepharitis market or expected to get launched during the study period. The analysis covers Blepharitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Blepharitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Blepharitis Therapies and Key Companies

*
XDEMVY: Tarsus Pharmaceuticals

*
Pimecrolimus 0.3% ophthalmic ointment: Famy Life Sciences

*
TP-03: Tarsus Pharmaceuticals

*
PMP2207: Premark Pharma

*
Erythromycin: Bausch & Lomb Incorporated

*
TP-03: Tarsus Pharmaceuticals, Inc.

*
NCX 4251: Nicox Ophthalmics, Inc.

*
Azithromycin: Laboratoires Thea

*
Fluticasone Propionate: Nicox Ophthalmics, Inc.

*
ISV-502: Sun Pharmaceutical

*
Lotilaner: LianBio LLC

*
AzaSite Registered : Merck Sharp & Dohme

*
AXR-270: AxeroVision, Inc.

*
Tobradex ST: Alcon Research

*
Posiformin: Ursapharm Arzneimittel

*
COL-101: Galderma R&D

*
KPI-121: Kala Pharmaceuticals

*
Moxifloxacin: Alcon Research

Discover more about therapies set to grab major Blepharitis market share @ Blepharitis Treatment Market [https://www.delveinsight.com/sample-request/blepharitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Blepharitis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Blepharitis Companies: Famy Life Sciences, Tarsus Pharma, Akorn Inc., Allergan Plc, Bausch Health Companies, Inc., Novartis AG and Pfizer Inc., Nicox Ophthalmics, Inc., Laboratoires Thea, Sun Pharmaceutical, LianBio LLC, Merck Sharp & Dohme, AxeroVision, Inc., Alcon Research, Ursapharm Arzneimittel, Galderma R&D, Kala Pharma, and others

*
Key Blepharitis Therapies: XDEMVY, Pimecrolimus 0.3% ophthalmic ointment, TP-03, PMP2207, Erythromycin, NCX 4251, Azithromycin, Fluticasone Propionate, ISV-502, Lotilaner, AzaSite Registered , AXR-270, Tobradex ST, Posiformin, COL-101, KPI-121, Moxifloxacin, and others

*
Blepharitis Therapeutic Assessment: Blepharitis current marketed and Blepharitis emerging therapies

*
Blepharitis Market Dynamics: Blepharitis market drivers and Blepharitis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Blepharitis Unmet Needs, KOL's views, Analyst's views, Blepharitis Market Access and Reimbursement

To know more about Blepharitis companies working in the treatment market, visit @ Blepharitis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/blepharitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Blepharitis Market Report Introduction

2. Executive Summary for Blepharitis

3. SWOT analysis of Blepharitis

4. Blepharitis Patient Share (%) Overview at a Glance

5. Blepharitis Market Overview at a Glance

6. Blepharitis Disease Background and Overview

7. Blepharitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Blepharitis

9. Blepharitis Current Treatment and Medical Practices

10. Blepharitis Unmet Needs

11. Blepharitis Emerging Therapies

12. Blepharitis Market Outlook

13. Country-Wise Blepharitis Market Analysis (2020-2034)

14. Blepharitis Market Access and Reimbursement of Therapies

15. Blepharitis Market Drivers

16. Blepharitis Market Barriers

17. Blepharitis Appendix

18. Blepharitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=blepharitis-market-positioned-for-accelerated-development-through-2034-delveinsight-finds-akorn-inc-allergan-plc-bausch-health-companies-inc-novartis-ag-and-pfizer-inc-nicox-ophthalmics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.